Круглосуточно

+7 (965) 177 17 74


бесплатно по России
cbc40e52
img

курси 23797 акт описи наследственноджо имусгества с орузгием 246 711 пгп

img

The current COVID-19 pandemic caused by SARS-CoV-2 has become a global health emergency. Treatment of chronic inflammatory bowel disease (CIBD) according to the standards includes the use of 5-aminosalicylic acid (5-ASA), corticosteroids, cytostatics, and biological therapy. However, these treatments can weaken the immune system, which potentially puts COPD patients at increased risk of infections and infectious diseases, including COVID-19. Therefore, patients with CVD have a greater risk of developing COVID-19 and more severe clinical course, or even death, compared to the general population.

Treatment with corticosteroids (especially prednisolone ≥20 mg/day or equivalent) is associated with an increased risk of infection. However, it is unclear whether corticosteroid therapy is associated with an increased risk of developing COVID-19 or its complications. Data on budesonide, a topical corticosteroid with low systemic bioavailability, show that these drugs are associated with significantly fewer side effects compared to systemic corticosteroids and their side effects are close to placebo. If possible, corticosteroids should be avoided and a rapid dose reduction considered, and a switch to budesonide is recommended. This must be taken into account, taking into account the risk of exacerbation of CKD. If a patient with COPD is in contact with a person with COVID-19 or develops COVID-19, it is recommended to gradually reduce the dose of corticosteroids, the use of budesonide is preferred, but taking into account the severity of COPD and the risk of exacerbation.

At present, the risk of increased circulation of vaccine-related polioviruses and associated outbreaks with a low level of vaccination coverage against the background of the use of an oral vaccine is also complicated by military operations in the country, leading to the destruction of the infrastructure of cities and towns, intensive migration and evacuation of the population. Ukraine, and to regions where there are no active hostilities (Chernivtsi, Transcarpathian, Lvov, Volyn regions). These areas were the ones with the lowest polio vaccination rates in 2021.

img

It is the transition to the use of IPV in Ukraine for all doses of the Immunization Schedule that should be the next task for vaccination. For this, several mechanisms can be used, including humanitarian assistance, the conclusion of planned direct contracts with vaccine manufacturers based on the needs of the required composition of vaccines according to the Calendar, in particular, taking into account the existence of modern combined vaccines with IPV, which can also be used at an older age. In the absence of combination vaccines with IPV, IPV can be used as a single vaccine.


Контакты
  • г. Москва,
  • м. Отрадное,
  • Высоковольтный проезд, д. 1, к. 7

+7 (965) 177 17 74

  • Режим работы:

10:00 до 20:00 пн-пт

10:00 до 18:00 сб-вс

Забор анализов:

9:00 до 20:00 пн-пт

9:00 до 18:00 сб-вс